Earlier this year, MSDC reported that a Phase IIa clinical trial in type 2 diabetic patients showed that MSDC-0160 can improve insulin response and lower glucose in individuals with type 2 diabetes without producing the weight gain seen with currently marketed PPAR-activating insulin sensitizers. MSDC-0160 and MSDC's other insulin sensitizers work through a novel target discovered by the company's founders while minimizing PPAR activation.

Numerous scientific studies have shown a link between type 2 diabetes, cognitive impairment and Alzheimer's disease. Some studies have implied that measures to prevent or control diabetes may lower the risk of dementia and suggested that certain diabetes drugs should be tested to find out whether they can help Alzheimer's patients.

"This funding from the ADDF is an important first step in what could be a key development in the treatment of Alzheimer's," said Jerry Colca, president and chief scientific officer of MSDC. "For MSDC, if our compounds can reverse cognitive impairments in animal models, this may have important implications for the treatment of type 2 diabetes as well."

SOURCE Metabolic Solutions Development Company